Bifidobacteriaceae family diversity in gut microbiota of patients with renal failure

2020 ◽  
Author(s):  
Gholamreza Hanifi ◽  
Hamid Tayebi Khosroshahi ◽  
Reza Shapouri ◽  
Mohammad Asgharzadeh ◽  
Hossein Samadi Kafil
Keyword(s):  
Gut Microbiota ◽  
Control Group ◽  
Disease Group ◽  
Bifidobacterium Adolescentis ◽  
Fecal Samples ◽  
Health Promoting ◽  
Stage Renal Disease ◽  
End Stage ◽  
And Control ◽  
Esrd Patients

Abstract Background: Bifidobacteriaceae family are belonged to the gut microbiota that could exhibit probiotic or health promoting effects on the host. Several studies suggested that gut microbiota are quantitative and qualitative altered in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The present study was aimed to assess the members of Bifidobacteriaceae family in fecal samples of patients with CKD and ESRD in compared to non-CKD/ESRD patients to find any changes of their counts in these patients.Methods: Twenty fresh fecal samples of patients with CKD/ESRD and twenty from non-CKD/ESRD patients were included. The whole DNA of fecal samples were extracted and the gut microbiota composition was analyzed by next generation sequencing (NGS) method.Results: Total 651 strains were identified from 40 fecal samples, which 8 (1.23%) strains were identified as family Bifidobacteriaceae. The most abundance species in both control and disease group were Bifidobacterium adolescentis (2.10% ± 1.05% vs. 1.98% ± 1.53%, respectively) and the lowest abundance species in disease group was Bifidobacterium animalis subsp. lactis (0.0007% ± 0.0009%).Conclusions: There was no significant differentiation in the abundance of various species between disease group and control group (p<0.05). This study has confirmed that the members of Bifidobacteriaceae family are not alters in patients with CKD/ESRD.

Differences in Gut Microbiota Profiles and Functions Between End-stage Renal Disease and Healthy Populations 

2020 ◽  
Author(s):  
Ping-Hsun Wu ◽  
Ting-Yun Lin ◽  
Hsiu J. Ho ◽  
Ching-Hung Tseng ◽  
Yi-Ting Lin ◽  
...  
Keyword(s):  
Amino Acid ◽  
Gut Microbiota ◽  
End Stage Renal Disease ◽  
Amino Acid Metabolism ◽  
Acid Metabolism ◽  
Α Diversity ◽  
Stage Renal Disease ◽  
End Stage ◽  
And Control ◽  
Esrd Patients

Abstract Background: Patients with end-stage renal disease (ESRD) have extremely high risks of mortality and morbidity, as well as altered gut microbiota and impaired intestinal barrier function. The translocation of gut-derived molecules in ESRD contributes to systemic complications. In this study, we evaluated the gut microbiome difference in ESRD patients compared to age- and gender-matched subjects without kidney disease in discovery and validation cohorts.Results: Compared to controls with normal renal function, an increased α-diversity and distinct β-diversity were found in ESRD subjects. The increase in α-diversity was correlated with protein-bound uremic toxins, particularly hippuric acid. A higher microbial dysbiosis index (MDI) was found in ESRD patients with the following enriched genera: Facealibacterium, Ruminococcus, Fusobacterium, Dorea, Anaerovorax, Sarcina, Akkemansia, Streptococcus, and Dysgonomonas. MDI at the genus level demonstrated highly differentiated accuracies between ESRD and control subjects in the discovery cohort (area under the curve [AUC] of 81.9%) and between ESRD and control subjects in the validation cohort (AUC of 83.2%). On functional enrichment analysis with gut metabolic modules, ESRD subjects presented with increased saccharide and amino acid metabolism when compared with matched controls.Conclusions: An enriched but dysbiotic gut microbiota was presented in ESRD patients, in which the bacteria that were present increase amino acid metabolism linked to the production of protein-bound uremic toxins.

scholarly journals Diffusion Tensor Imaging Features of Watershed Segmentation Algorithm for Analysis of the Relationship between Depression and Brain Nerve Function of Patients with End-Stage Renal Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Feng Zhu ◽  
Jiao Xu ◽  
Mei Yang ◽  
Haitao Chi
Keyword(s):  
End Stage Renal Disease ◽  
Diffusion Tensor ◽  
Segmentation Algorithm ◽  
Control Group ◽  
Nerve Function ◽  
Watershed Segmentation ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Relationship ◽  
Esrd Patients

The aim of this research was to explore the relationship between depression and brain nerve function in patients with end-stage renal disease (ESRD) and long-term maintenance hemodialysis (MHD) based on watershed segmentation algorithm using diffusion tensor imaging (DTI) technology. A total of 29 ESRD patients with depression who received MHD treatment in the hemodialysis center of hospital were included as the research subjects (case group). A total of 29 healthy volunteers were recruited as the control group, and a total of 29 ESRD patients with depression and brain lesions were recruited as the control group (HC group). Within 24 h after hemodialysis, the blood biochemical indexes were collected before this DTI examination. All participants completed the neuropsychological scale (MoCA, TMT A, DST, SAS, and SDS) test. The original DTI data of all subjects were collected and processed based on watershed segmentation algorithm, and the results of automatic segmentation according to the image were evaluated as DSC = 0.9446, MPA = 0.9352, and IOU = 0.8911. Finally, the average value of imaging brain neuropathy in patients with depression in the department of nephrology was obtained. The differences in neuropsychological scale scores (PSQI, MoCA, TMTA, DST, SAS, and SDS) between the two groups were statistically significant ( P < 0.05 ). The differences of FA values in all the white matter partitions of Fu organs, except the cingulum of hippocampus (CgH) between the two groups, were statistically significant ( P < 0.05 ). ESRD and DTI quantitative detection under the guidance of watershed segmentation algorithm in MHD patients showed that ESRD patients can be early identified, so as to carry out psychological nursing as soon as possible to reduce the occurrence of depression, and then protect the brain nerve to reduce brain neuropathy.

scholarly journals Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Violeta Dopsaj ◽  
Aleksandra Topić ◽  
Miljan Savković ◽  
Neda Milinković ◽  
Ivana Novaković ◽  
...  
Keyword(s):  
Renal Disease ◽  
Diagnostic Accuracy ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Transferrin Saturation ◽  
Deficiency Anemia ◽  
Control Group ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background. Influence of TMPRSS6 A736V and HFE (C282Y and H63D) polymorphisms on serum hepcidin-25 levels and iron status parameters in end-stage renal disease (ESRD) patients stratified according to gender has not been previously investigated. In addition, we aimed to evaluate the diagnostic accuracy of the parameters to separate iron-deficiency anemia (IDA) from anemia of chronic disease. Materials and Methods. Iron status parameters and genetic analysis were performed in 126 ESRD patients and in 31 IDA patients as the control group. Results. ESRD patients had significantly higher ferritin and hepcidin-25 (<0.001) relative to IDA patients. Cut-off values with the best diagnostic accuracy were found for hepcidin ≥9.32 ng/mL, ferritin ≥48.2 μg/L, transferrin saturation ≥16.8%, and MCV ≥81 fL. Interaction between gender and HFE haplotypes for the hepcidin-25 and ferritin levels in ESRD patients (p=0.005, partial eta squared=0.09; p=0.027, partial eta squared=0.06, respectively) was found. Serum transferrin was influenced by the combined effect of gender and TMPRSS6 A736V polymorphism in ESRD patients (p=0.002, partial eta squared=0.07). Conclusion. Our findings could contribute to the further investigation of mechanisms involved in the pathophysiology and important gender-related involvement of the TMPRSS6 and HFE polymorphisms on anemia in ESRD patients.

scholarly journals Cytomegalovirus (CMV) and C-Reactive Protein (CRP) and their Association with Atherosclerosis in Patients with End Stage Renal Disease

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A M Okba ◽  
M A Raafat ◽  
M N Farres ◽  
N A Melek ◽  
M M Doss ◽  
...  
Keyword(s):  
Mean Value ◽  
Control Group ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage ◽  
Serum Crp ◽  
Atherosclerotic Changes ◽  
Esrd Patients

Abstract Background ESRD (end stage renal disease) is associated with an increase in the risk for cardiovascular disease, which can only be partially explained by known classical risk factors. However, chronic inflammation and endothelial dysfunction are key events in the development of atherosclerosis; both are observed in ESRD patients . The significance of C-Reactive Protein (CRP) and inflammation has increased over time, especially in the ESRD population. From being a simple marker, it now shown that CRP has an active participation in pro-atherosclerotic phenomenon including local pro-inflammatory and thrombotic events. Studies in the general population indicate the usefulness of CRP in prognosis and in monitoring response to therapy. Cytomegalovirus (CMV) is an important pathogen in immunocompromised individuals. Patients with ESRD display signs of frequent CMV re-activation, which may be caused by the uraemia-associated defect in cellular immunity. It has been well documented that hemodialysis patients have impaired immune response, which may result in higher prevalence rates of viral infections, including CMV. Infections in these patients may be due to primary infection or, more commonly, by reactivation of latent virus or re-infection with exogenous virus, which may be introduced by blood transfusion or kidney transplant. Infection with CMV is also considered a risk factor for progression of atherosclerotic disease. Methods CRP and CMV IgG level was measured in the blood samples of sixty adult patients diagnosed as ESRD, 30 ESRD patients with atherosclerotic changes(Group I) and 30 ESRD patients without atherosclerotic changes (Group II) and in comparison with 30 control subjects(Group III) (Control Group). Results The mean value of CRP in the control group (6.0 ± 4.2), the mean value in the ESRD patients with atherosclerotic changes group (15.8 ± 5.6) and the mean value in the ESRD patients without atherosclerotic changes group (11.2 ± 3.9),thus the mean values of CRP in ESRD patients groups were significantly higher than that of the control group (P &lt; 0.001) and the mean value of CRP in ESRD with atherosclerotic changes is significantly higher compared to ESRD without atherosclerotic changes group (P &lt; 0.001). Regarding CMV IgG antibodies it was significantly higher in ESRD patients compared to the control group and was also significantly higher in ESRD with atherosclerotic changes compared to ESRD without atherosclerotic changes. Conclusions ESRD are at greater risk of inflammatory reaction against factors originating from graft, fistula, dialysis membrane, infection sites. These reactions are associated with increased levels inflammatory markers such as serum CRP. Serum CRP seems to have a contribution in the development of cardiovascular complications in ESRD patients.CMV seropositivity is also significantly associated with atherosclerotic disease in ESRD patients. Our data suggest that the risk for progressive atherosclerosis is specifically increased in patients with an inflammatory response to CMV and elevated CRP level.

scholarly journals Effect of local papaverine on arteriovenous fistula maturation in patients with end-stage renal disease

2019 ◽  
Vol 41 (2) ◽  
pp. 185-192 ◽  
Author(s):  
Reza Manani ◽  
Gholamreza Kazemzadeh ◽  
Ali Saberi ◽  
Fatemeh Sadeghipour ◽  
Asghar Rahmani
Keyword(s):  
Renal Disease ◽  
Arteriovenous Fistula ◽  
End Stage Renal Disease ◽  
Control Group ◽  
Case Group ◽  
Maturation Time ◽  
Stage Renal Disease ◽  
End Stage ◽  
And Control ◽  
Fistula Maturation

Abstract Background: Arteriovenous fistula (AVF) maturation is one of the main concerns in patients with end-stage renal disease (ESRD) and finding a strategy for increasing success rate and accelerating fistula maturation is valuable. The aim of this study was to evaluate the effects of papaverine injection on AVF maturation and success rate. Method: This study was a randomized clinical trial that involved 110 patients with ESRD that were referred for AVF construction. Patients were allocated in papaverine group and control group with block randomization according to age and sex. In the case group, papaverine (0.1 or 0.2 cc) was injected locally within the subadventitia of artery and vein after proximal and distal control during AVF construction and in the control group, AVF construction was done routinely without papaverine injection. Results: Maturation time in case and control groups was 37.94 ± 11.49 and 44.23 ± 9.57 days, respectively (p=0.004). Hematoma was not seen in the case group but occurred in one patient in the control group. One patient of the case group developed venous hypertension. Four functional fistulas, 1 (1.8%) in the case group and 3 (5.5%) in the control group, failed to mature (p=0.618). Maturation rate did not differ between the two groups statistically (p=0.101). Conclusion: Local papaverine injection increased vessel diameter and blood flow, increasing shearing stress in both arterial and venous segment of recently created AVF. In this way, papaverine probably can decrease AVF maturation time without an increase in complications.

scholarly journals Effects of Peer Support Program on Self-Management in Patients with End-Stage Renal Disease Undergoing Hemodialysis

2020 ◽  
Vol 10 (2) ◽  
pp. 171-181 ◽  
Author(s):  
Fida' Husain ◽  
Henni Kusuma ◽  
Andrew Johan
Keyword(s):  
Peer Support ◽  
End Stage Renal Disease ◽  
Intervention Group ◽  
Support Programs ◽  
Self Management ◽  
Control Group ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End-stage renal disease (ESRD) patients undergoing hemodialysis require essential self-management to lifestyle changes to minimize the risk of complications, morbidity, and mortality. Efforts made to improve self-management of hemodialysis patients in previous studies were carried out by health workers that may not provide 'real' knowledge, while peer support programs carried out by patients as peers to share their experiences may provide more benefits.Purpose: The purpose of this study was to determine the effects of peer support programs on improving self-management in patients with ESRD undergoing hemodialysis.Methods: This study employed a quasi-experimental design and involved a total of 33 patients in the control group and 32 patients in the intervention group, who met the inclusion and exclusion criteria. The samples were recruited consecutively. The intervention of peer support programs was implemented through information support, emotional support, and mutual reciprocity in groups of 10-12 people to share experiences related to their self-management. The intervention was given for six sessions; each lasted for 30-45 minutes. The data were collected using the Indonesian version of the hemodialysis self-management instrument (HDSMI) and analyzed using a paired-sample t-test and independent-sample t-test.Results: The results showed that after the intervention, the mean score of self-management in the intervention group increased from 79.47±7.919 to 90.75±7.089, and in the control group, the mean increased from 81.88±8.291 to 82.12±7.692. After the implementation of peer support programs, there was a significant difference in the score of self-management between the intervention and control groups (p<0.001).Conclusion: Peer support programs gave an effect on increasing self-management in patients with ESRD undergoing hemodialysis. Peer support programs should be introduced early to ESRD patients undergoing hemodialysis so that they can learn about self-management from other patients.  

Impaired resistance artery function in patients with end-stage renal disease

2011 ◽  
Vol 120 (12) ◽  
pp. 525-536 ◽  
Author(s):  
Natallia Luksha ◽  
Leanid Luksha ◽  
Juan Jesús Carrero ◽  
Folke Hammarqvist ◽  
Peter Stenvinkel ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Nitrosative Stress ◽  
Control Group ◽  
Strong Impact ◽  
Arterial Distensibility ◽  
Functional Features ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

We investigated an effect of uraemia on structural and functional features of human resistance vasculature. Arteries (≈ 200 μm) isolated from subcutaneous fat biopsies obtained from 35 ESRD (end-stage renal disease) patients starting peritoneal dialysis and 30 matched controls were studied using isolated small artery bioassays. Flow-mediated dilatation was attenuated in ESRD patients compared with controls. NO (nitric oxide) contribution to flow was lacking in ESRD patients, but present in the controls. ADMA (asymmetrical dimethyl L-arginine) levels were higher in the ESRD group compared with the control group. Dilatation in response to acetylcholine was reduced in ESRD patients compared with controls, but response to NO donor was similar. Expression of nitrotyrosine and heat shock proteins 70 and 27, but not 90, was increased in arteries from ESRD patients compared with controls. Arterial remodelling was absent in ESRD patients. There was no difference between the groups in myogenic tone, vascular reactivity or sensitivity to several vasoconstrictors. Arterial distensibility, reflecting passive properties of the vascular wall, was reduced in ESRD patients compared with controls. Exclusion of ESRD patients with diabetes and/or cardiovascular disease from analyses had no influence on the main findings. Thus we propose that uraemia has a strong impact on endothelial function and passive properties of the arterial wall of human peripheral resistance vasculature. The reduced contribution of NO to flow stimulus via enhanced nitrosative stress and higher plasma concentrations of ADMA may suggest potential mechanisms behind endothelial dysfunction in the resistance peripheral circulation in ESRD.

scholarly journals THE IGF-1 LEVEL OF ESRD PATIENTS AND ITS RISK FACTORS

2014 ◽  
Vol 21 (1) ◽  
Author(s):  
Titiek Hidayati ◽  
Yuningtyaswari Yuningtyaswari ◽  
Ahmad Hamim Sadewa ◽  
Marsetyawan HNE Soesatyo
Keyword(s):  
Plasma Level ◽  
End Stage Renal Disease ◽  
Odds Ratio ◽  
Smoking Status ◽  
Bivariate Analysis ◽  
Control Groups ◽  
Stage Renal Disease ◽  
End Stage ◽  
And Control ◽  
Esrd Patients

Objective: To identify the Insulin-like Growth Factor–1 (IGF-1) level of End Stage Renal Disease (ESRD) and non ESRD populations, and correlation between IGF-1level and ESRD incidences. Material & Method: This case study was carried out in Yogyakarta with 72 volunteers. The cases involved Chronic Kidney Disease (CKD) patients. The controls were non-CKD patients. CKD parameters were established with PERNEFRI diagnostic criteria. Comparison of IGF-1 levels between case and control groups was performed through ANOVA, with confidence level of 95%. Bivariate analysis to identify the correlation between IGF-1 plasma level, smoking status, illness history and body mass index (BMI) by determining odds ratio (OR) of individual risk factor of p < 0.05. Results: We enrolled 72 volunteers, 45 male and 27 female subjects. Of the 45 male patients, 15 CKD and 30 non CKD patients served as cases and controls, respectively. The difference in plasma IGF-1 level was detected in the case and control groups (42.01 ± 10.66 vs. 56.05 ± 24.91) (p < 0.05). The result of bivariate analysis showed passive smoking status, IGF-1 plasma level, DM history and hypertensive illness history had correlation with ESRD incidence with odds ratios of 7.88 (p < 0.005; CI: 1.6-37.5) for passive smokers, 4.3 (p < 0.05, CI: 1.36 to 13.33) for IGF-1 level, 21.5 (p < 0.05; CI) for DM history and 12.4 (p < 0.05; CI: 3.7 to 41) for hypertensive history. Conclusion: There was difference in IGF-1 plasma level between ESRD and non-ESRD patients. The IGF-1 plasma level, passive smoking status, diabetes history, and hypertensive history have correlation with ESRD incidence.Keywords: Insulin-like Growth Factor–1 level, End Stage Renal Disease, case control, odds ratio.

scholarly journals The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses

2021 ◽  
Vol 11 ◽  
Author(s):  
Dan Luo ◽  
Wenbo Zhao ◽  
Zhiming Lin ◽  
Jianhao Wu ◽  
Hongchun Lin ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Gut Microbiota ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Before And After ◽  
Patient Prognosis ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Relationship ◽  
Esrd Patients

Gut microbiota alterations occur in end-stage renal disease (ESRD) patients with or without dialysis. However, it remains unclear whether changes in gut microbiota of dialysis ESRD patients result from dialysis or ESRD, or both. Similarly, there is a dearth of information on the relationship between gut microbiota and ESRD prognoses. We collected fecal samples and tracked clinical outcomes from 73 ESRD patients, including 33 pre-dialysis ESRD patients, 19 peritoneal dialysis (PD) patients, and 21 hemodialysis (HD) patients. 16S rRNA sequencing and bioinformatics tools were used to analyze the gut microbiota of ESRD patients and healthy controls. Gut microbiota diversity was different before and after dialysis. Bacteroidetes were significantly deceased in HD patients. Twelve bacterial genera exhibited statistically significant differences, due to dialysis (all P &lt; 0.05, FDR corrected). HD reversed abnormal changes in Oscillospira and SMB53 in pre-dialysis patients. Functional predictions of microbial communities showed that PD and HD altered signal transduction and metabolic pathways in ESRD patients. Furthermore, Bacteroides and Phascolarctobacterium were associated with cardiovascular mortality. Dorea, Clostridium, and SMB53 were related to peritonitis in PD patients. This study not only demonstrated differences in gut microbiota between pre-dialysis and dialysis ESRD patients, but also firstly proposed gut bacteria may exert an impact on patient prognosis.

Exploring the Association between Changes in Dialysis Reimbursement Policies and Care Outcomes of Peritoneal Dialysis

2020 ◽  
Author(s):  
Ray-E Chang ◽  
Shih-Pi Lin ◽  
Feng-Jung Yang ◽  
Robert C. Myrtle
Keyword(s):  
Peritoneal Dialysis ◽  
Cost Effective ◽  
Control Group ◽  
Technical Failure ◽  
Care Providers ◽  
Before And After ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Impact ◽  
Esrd Patients

Abstract Background: Except for renal transplantation, peritoneal dialysis (PD) is considered to be relatively cost-effective option for end-stage renal disease (ESRD) patients. Less than 7% of ESRD patients receiving PD in Taiwan, and the promising benefits of PD treatment influenced health policy makers to seek ways to encourage PD utilization. The purpose of this study is to evaluate the effect of their policy initiatives.Methods: An observational longitudinal study using a before-and-after analysis was conducted. The propensity score matching technique was employed to match PD patients before and after the introduction of Taiwan’s efforts to encourage PD utilization in ESRD patients, and the change in PD technical failure was analyzed. HD patients were also matched as the control group to assess the impact of Taiwan’s PD utilization encouraging policies on mortality in PD patients. The competing risk regression approach for survival analysis was adopted in our study.Results: The results showed that while the PD encouraging policies had increased the PD utilization, the increase in PD utilization was accompanied by an increase in technique failure and an increase in mortality.Conclusions: The adoption of new treatments which may benefit patients and incentives to change physician practice behaviors require more disciplined and carefully managed implementation efforts. Care providers need to be equipped by adequate training and sufficient manpower as part of the policy package.

Sign in / Sign up

Export Citation Format

Share Document